沛嘉醫療-B(09996.HK):Edwards Lifesciences收購公司的許可合作伙伴JenaValve
格隆匯7月25日丨沛嘉醫療-B(09996.HK)發佈公吿,2024年7月24日,JenaValve Technology, Inc.(“JenaValve”)通知公司,Edwards Lifesciences Corporation已同意透過合併事項方式收購JenaValve,而Edwards Lifesciences Corporation為一家在紐約證券交易所上市的公司,併為以患者為中心的結構性心臟病及重症監護監測創新的全球領導者。合併事項的完成須遵守合併協議所述的條款及條件,包括達成慣常條件。
JenaValve為一家美國醫療器材公司。於2021年12月,集團獲得在大中華地區(“區域”)開發、製造及商業化治療主動脈瓣反流(AR)及主動脈瓣狹窄(AS)的JenaValve Trilogy™經導管心臟瓣膜系統(THV系統)的獨佔許可。隨後,公司選擇重塑該技術品牌名為TaurusTrio™,並在中國開展針對嚴重AR的多中心註冊臨牀試驗。試驗的患者入組已於2024年1月成功完成。
合併事項不會影響集團與JenaValve的獨佔許可或集團開發及商業化TaurusTrio™的權利。合併事項完成後,集團將維持上述獨佔許可,以在區域開發AR及AS的THV系統。公司相信,合併事項表明對利用JenaValve技術治療 AR的未來前景充滿信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.